In addition, Mahadevan et al. (41) recently showed that KRAS inhibition in a genetic model for pancreatic cancer also led to prolonged survival in a combination therapy with anti–PD-1 and anti–CTLA-4. This evidence concerns the gene KRAS and familial pancreatic carcinoma.